Abstract: The present invention is directed to a continuous process for producing a foamable celluloid product by introducing a solid component (comprising nitrocellulose, chemical blowing agent (CBA), stabilizer and alcohol) and a liquid component (comprising camphor and acetone) into a mixer/devolatilizer machine where the chamber is under atmospheric pressure and having significant overhead space. The chamber is comprised of two zones wherein the first zone has a temperature that is less than the second zone and at least one rotor comprising hollow, temperature-controlled arms having a tilted angle affixed to the rotors. The rotors of the mixer/devolatilizer machine act to mix the solid and liquid components under lower shearing forces, lower mechanical stress and longer residence times than those used by twin-screw extruders.

Abstract: Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.

Abstract: Provided are methods of treating cancer in a human subject. The method includes selecting a subject in need of treatment of cancer; administering to the subject a therapeutically effective amount of gedatolisib at least once a week for a period of three weeks; discontinuing administration of gedatolisib for a period of one week; and resuming administration of gedatolisib at least once a week following the period of discontinuation. The administration for at least a period of three weeks and discontinued administration for at least a period of one week constitutes a cycle, where the cycle is repeated for at least two cycles.

Abstract: Provided herein are methods for determining the functional status of G-protein coupled receptor (GPCR) signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a RAS node or receptor tyrosine kinase (RTK) targeted therapeutic. Also provided are methods for determining whether a GPCR signaling pathway is ultrasensitive in a diseased cell sample from a subject. Methods of administering a selected RAS node or RTK targeted therapeutic agent to the subject are also provided.

Abstract: Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.

Abstract: A method, system, and network providing hardware and software inventorying and monitoring provide the status of a local network of interconnected information technology devices. A user downloads and installs a local network monitoring software program from an online source onto a host computer system. The local network monitoring software system initiates an inventory of all information technology devices associated with said local network of information technology devices. Also, the local network monitoring software determines the operational status of the information technology devices and the status of software programs installed on the information technology devices. The results of the inventory and status determinations are presented to the host computer system.

Abstract: A method, system, and network providing hardware and software inventorying and monitoring provide the status of a local network of interconnected information technology devices. A user downloads and installs a local network monitoring software program from an online source onto a host computer system. The local network monitoring software system initiates an inventory of all information technology devices associated with said local network of information technology devices. Also, the local network monitoring software determines the operational status of the information technology devices and the status of software programs installed on the information technology devices. The results of the inventory and status determinations are presented to the host computer system.

Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.

Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.

Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.

Abstract: A method, system, and network providing hardware and software inventorying and monitoring provide the status of a local network of interconnected information technology devices. A user downloads and installs a local network monitoring software program from an online source onto a host computer system. The local network monitoring software system initiates an inventory of all information technology devices associated with said local network of information technology devices. Also, the local network monitoring software determines the operational status of the information technology devices and the status of software programs installed on the information technology devices. The results of the inventory and status determinations are presented to the host computer system.

Abstract: A method, system, and network providing hardware and software inventorying and monitoring provide the status of a local network of interconnected information technology devices. A user downloads and installs a local network monitoring software program from an online source onto a host computer system. The local network monitoring software system initiates an inventory of all information technology devices associated with said local network of information technology devices. Also, the local network monitoring software determines the operational status of the information technology devices and the status of software programs installed on the information technology devices. The results of the inventory and status determinations are presented to the host computer system.

Abstract: Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.

Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.

Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.

Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.

Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.

Abstract: A method, system, and network providing hardware and software inventorying and monitoring provide the status of a local network of interconnected information technology devices. A user downloads and installs a local network monitoring software program from an online source onto a host computer system. The local network monitoring software system initiates an inventory of all information technology devices associated with said local network of information technology devices. Also, the local network monitoring software determines the operational status of the information technology devices and the status of software programs installed on the information technology devices. The results of the inventory and status determinations are presented to the host computer system.

Abstract: A method, system, and network for interfacing the work-flow monitoring and reporting of a host computer, a local network of information technology devices, a community of network users, and third party vendors is provided. This includes processes and systems for initiating an inventory, including software, of a plurality of information technology devices associated with a local network of information technology devices from a host computer and determining the operational status of the information technology devices associated with the local network. The operational status of the information technology devices associated with the local network is monitored and presented to a host computer. Needs relating to the local network are identified and determined and a purchasing platform for purchasing product solutions from third party vendors is provided.

Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.